Roche's biologics sales to hit $30bn by 2018
This article was originally published in Scrip
Executive Summary
By 2018, $30bn, or nearly four-fifths of Roche's total pharmaceutical sales, will come from biological therapies, according to analysis by Datamonitor Healthcare. The proportion is set to rise from an already high 74% in the first half of 2013 to 78% by 2018.